#China #Hangzhou #Medical Devices #Zylox-Tonbridge

Zylox-Tonbridge Anticipates Strong Growth with Profit Forecast for 2025

Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), a prominent player in China's medical device sector, particularly in peripheral and neurovascular interventions, has recently issued a positive profit alert. As of June 30, 2025, the company is projecting a notable increase in its financial performance, expecting to surpass RMB 115 million in net profit.

Strong Financial Forecast

According to preliminary, unaudited figures, Zylox-Tonbridge anticipates its revenue to exceed RMB 480 million for the first half of 2025. This marks a remarkable year-on-year growth of around 31.1%, and the projected net profit indicates a stunning increase of about 66.9% compared to the same period last year. Such promising financial results highlight the company's successful strategic maneuvers and compelling market presence.

Key Drivers of Growth

The substantial growth in revenue and net profit can be attributed to the company's ongoing expansion in the neurovascular and peripheral vascular intervention arenas. Zylox-Tonbridge has seen significant sales growth from several key products, including:

• - Kylin™ Flow Diverter
• - Neurovascular guidewires
• - UltraFree® Drug-Coated PTA Balloon Catheter
• - Zylox Octoplus™ Vena Cava Filter

These products have not only generated impressive revenue but have also contributed to the increasing market share that the company is experiencing.

Commitment to Innovation

In addition to commercial success, Zylox-Tonbridge is also accelerating the launch of innovative products. In the first half of 2025, it received regulatory approval from China's National Medical Products Administration (NMPA) for the ZYLOX Eagle™ Peripheral Thrombus aspiration system. This addition to its product lineup enhances the company’s ability to deliver comprehensive treatment solutions to its growing customer base.

International Expansion Efforts

Zylox-Tonbridge's focus on innovation is paralleled by its efforts to penetrate international markets. The company has achieved key regulatory approvals for several of its core products, which are now seeing initial sales in emerging markets across Southeast Asia, the Middle East, and South America. This broader reach represents a strategic shift towards global expansion and positions Zylox-Tonbridge for continued success.

Future Outlook

As the company looks to the future, Zylox-Tonbridge remains dedicated to its mission of "Innovation for Quality Life." The firm plans to consistently invest in medical technologies that are not only of high quality but also cost-effective for patients worldwide. By promoting innovative healthcare solutions, Zylox-Tonbridge aims to play a crucial role in the sustainable development of the global healthcare ecosystem.

In conclusion, the projected financial results for Zylox-Tonbridge solidify its status as a leader in the medical device market. With a clear focus on expansion, innovation, and global reach, the company is poised for continued growth and success in the coming years.